Frontiers in Neural Circuits (Oct 2023)
GABAergic signaling in alcohol use disorder and withdrawal: pathological involvement and therapeutic potential
- Ravinder Naik Dharavath,
- Celeste Pina-Leblanc,
- Celeste Pina-Leblanc,
- Victor M. Tang,
- Victor M. Tang,
- Victor M. Tang,
- Victor M. Tang,
- Victor M. Tang,
- Victor M. Tang,
- Matthew E. Sloan,
- Matthew E. Sloan,
- Matthew E. Sloan,
- Matthew E. Sloan,
- Matthew E. Sloan,
- Matthew E. Sloan,
- Matthew E. Sloan,
- Yuliya S. Nikolova,
- Yuliya S. Nikolova,
- Peter Pangarov,
- Anthony C. Ruocco,
- Anthony C. Ruocco,
- Anthony C. Ruocco,
- Anthony C. Ruocco,
- Kevin Shield,
- Daphne Voineskos,
- Daphne Voineskos,
- Daphne Voineskos,
- Daniel M. Blumberger,
- Daniel M. Blumberger,
- Daniel M. Blumberger,
- Isabelle Boileau,
- Isabelle Boileau,
- Isabelle Boileau,
- Isabelle Boileau,
- Nikki Bozinoff,
- Nikki Bozinoff,
- Philip Gerretsen,
- Philip Gerretsen,
- Philip Gerretsen,
- Philip Gerretsen,
- Erica Vieira,
- Erica Vieira,
- Osnat C. Melamed,
- Osnat C. Melamed,
- Etienne Sibille,
- Etienne Sibille,
- Etienne Sibille,
- Lena C. Quilty,
- Lena C. Quilty,
- Thomas D. Prevot,
- Thomas D. Prevot
Affiliations
- Ravinder Naik Dharavath
- Campbell Family Mental Health Research Institute of CAMH, Toronto, ON, Canada
- Celeste Pina-Leblanc
- Campbell Family Mental Health Research Institute of CAMH, Toronto, ON, Canada
- Celeste Pina-Leblanc
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
- Victor M. Tang
- Campbell Family Mental Health Research Institute of CAMH, Toronto, ON, Canada
- Victor M. Tang
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Victor M. Tang
- Addiction Division, CAMH, Toronto, ON, Canada
- Victor M. Tang
- Division of Neurosciences and Clinical Translation, Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Victor M. Tang
- Institute of Medical Science, University of Toronto, Toronto, ON, Canada
- Victor M. Tang
- Institute of Mental Health Policy Research, CAMH, Toronto, ON, Canada
- Matthew E. Sloan
- Campbell Family Mental Health Research Institute of CAMH, Toronto, ON, Canada
- Matthew E. Sloan
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
- Matthew E. Sloan
- Addiction Division, CAMH, Toronto, ON, Canada
- Matthew E. Sloan
- Division of Neurosciences and Clinical Translation, Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Matthew E. Sloan
- Department of Psychological Clinical Science, University of Toronto Scarborough, Toronto, ON, Canada
- Matthew E. Sloan
- Institute of Medical Science, University of Toronto, Toronto, ON, Canada
- Matthew E. Sloan
- Institute of Mental Health Policy Research, CAMH, Toronto, ON, Canada
- Yuliya S. Nikolova
- Campbell Family Mental Health Research Institute of CAMH, Toronto, ON, Canada
- Yuliya S. Nikolova
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Peter Pangarov
- Campbell Family Mental Health Research Institute of CAMH, Toronto, ON, Canada
- Anthony C. Ruocco
- Campbell Family Mental Health Research Institute of CAMH, Toronto, ON, Canada
- Anthony C. Ruocco
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Anthony C. Ruocco
- Temerty Centre for Therapeutic Brain Intervention, CAMH, Toronto, ON, Canada
- Anthony C. Ruocco
- 0Department of Psychology, University of Toronto Scarborough, Toronto, ON, Canada
- Kevin Shield
- Institute of Mental Health Policy Research, CAMH, Toronto, ON, Canada
- Daphne Voineskos
- Campbell Family Mental Health Research Institute of CAMH, Toronto, ON, Canada
- Daphne Voineskos
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Daphne Voineskos
- Temerty Centre for Therapeutic Brain Intervention, CAMH, Toronto, ON, Canada
- Daniel M. Blumberger
- Campbell Family Mental Health Research Institute of CAMH, Toronto, ON, Canada
- Daniel M. Blumberger
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Daniel M. Blumberger
- Temerty Centre for Therapeutic Brain Intervention, CAMH, Toronto, ON, Canada
- Isabelle Boileau
- Campbell Family Mental Health Research Institute of CAMH, Toronto, ON, Canada
- Isabelle Boileau
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
- Isabelle Boileau
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Isabelle Boileau
- 1Brain Health Imaging Centre, CAMH, Toronto, ON, Canada
- Nikki Bozinoff
- Campbell Family Mental Health Research Institute of CAMH, Toronto, ON, Canada
- Nikki Bozinoff
- 2Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada
- Philip Gerretsen
- Campbell Family Mental Health Research Institute of CAMH, Toronto, ON, Canada
- Philip Gerretsen
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Philip Gerretsen
- Institute of Medical Science, University of Toronto, Toronto, ON, Canada
- Philip Gerretsen
- 1Brain Health Imaging Centre, CAMH, Toronto, ON, Canada
- Erica Vieira
- Campbell Family Mental Health Research Institute of CAMH, Toronto, ON, Canada
- Erica Vieira
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Osnat C. Melamed
- Campbell Family Mental Health Research Institute of CAMH, Toronto, ON, Canada
- Osnat C. Melamed
- 2Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada
- Etienne Sibille
- Campbell Family Mental Health Research Institute of CAMH, Toronto, ON, Canada
- Etienne Sibille
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
- Etienne Sibille
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Lena C. Quilty
- Campbell Family Mental Health Research Institute of CAMH, Toronto, ON, Canada
- Lena C. Quilty
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Thomas D. Prevot
- Campbell Family Mental Health Research Institute of CAMH, Toronto, ON, Canada
- Thomas D. Prevot
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- DOI
- https://doi.org/10.3389/fncir.2023.1218737
- Journal volume & issue
-
Vol. 17
Abstract
Alcohol is one of the most widely used substances. Alcohol use accounts for 5.1% of the global disease burden, contributes substantially to societal and economic costs, and leads to approximately 3 million global deaths yearly. Alcohol use disorder (AUD) includes various drinking behavior patterns that lead to short-term or long-lasting effects on health. Ethanol, the main psychoactive molecule acting in alcoholic beverages, directly impacts the GABAergic system, contributing to GABAergic dysregulations that vary depending on the intensity and duration of alcohol consumption. A small number of interventions have been developed that target the GABAergic system, but there are promising future therapeutic avenues to explore. This review provides an overview of the impact of alcohol on the GABAergic system, the current interventions available for AUD that target the GABAergic system, and the novel interventions being explored that in the future could be included among first-line therapies for the treatment of AUD.
Keywords
